Inhibition of NO-synthase and degranulation of rat omental mast cells in vitro by Northover, A. M. & Northover, B. J.
Research Paper
Mediators of Inflammation 5, 257-261 (1996)
MAST cell amines, platelet-activating factor (PAF), Inhibition of NO-synthase and
thromboxanes and leukotrienes have been
shown to be released during nitric oxide-synthase degranulation of rat omentai mast
inhibition in the rat intestine. Mast cells in rat ce[ls in vitro
isolated omentum (OMCs) or isolated from the
rat peritoneal cavity (PMCs) have been used here
to investigate the relationship(s) between these
agents. N-nitro-L-arginine methyl ester (L-NAME, A.M. Northover
cA and B. J. Northover
100 IM) caused some degranulation of OMCs, but
no enhancement of histamine release from PMCs.
PAF (5 IM) and U46619 (1 IM) degranulated Department of Pharmaceutical Sciences, School of OMCs and enhanced histamine release from
PMCs. Pre-treatment of the omentum with Applied Sciences, De Montfort University, Leicester
BN52021 (10 IM) inhibited degranulation of LE1 9BH, UK
OMCs in response to L-NAME, PAF or U46619. Pre-
treatment with 1-benzylimidazole (5 or 50 IM)
inhibited the effect of L-NAME but not that of CACorresponding Author
PAF. Indomethacin (1 IM) or sodium nitroprus-
side (10 IM) also inhibited the effects of L-NAME,
but nordihydroguaiaretic acid (30 IM) did not. In
PMCs BN52021 inhibited PAF-induced, but not
U46619-induced, release of histamine. These
results suggest that inhibition of nitric oxide-
synthase in the omentum by L-NAME allows
thromboxanes to release PAF, which in turn
degranulates and releases histamine from OMCs.
Key words: BN52021, Indomethacin, Mast cells, N-nitro-t-
arginine methyl ester, Nitric oxide-synthase, Nordihy-
droguaiaretic acid, 1-Benzylimidazole, Platelet activating
factor
In the present work we have investigated the Introduction possible relationship(s) between these various
Degranulation of mast cells occurs during inhibitors/antagonists and the co-administration
ischaemia/reperfusion injury in both the rat of L-NAME. The study has focused on mast cell
mesentery and small intestine,
2 and it can be degranulation in the presence of such agents.
enhanced by prior administration of N-nitro-- Two methods have been used involving, firstly,
arginine methyl ester (L-NAME), a NO-synthase mast cells in situ in rat omental milky spots
inhibitor, or it can be inhibited by prior adminis- (OMCs) and, secondly, mast cells isolated from
tration of sodium nitroprusside (SNP), an NO the rat by peritoneal lavage (PMCs).
donor. Epithelial permeability to 51Cr in rat
small intestine is also increased by L-NAME and Methods this is associated with mucosal mast cell degran-
ulation. We have shown recently
4 that the L- Omental mast cells.. Female rats weighing about
NAME-induced increase in microvascular perme- 250g were killed by inhalation of chloroform
ability to injected colloidal carbon in the rat vapour. After opening the abdomen with a
small intestine is prevented by pre-treatment with midline incision followed by a lateral subcostal
cyproheptadine, a mixed histamine and 5-hydroxy- incision, the lesser omenmm was quickly
tryptamine receptor antagonist. Other workers removed into a beaker of normal saline (NS) and
have shown an increase in albumin leakage in then cut into five pieces of approximately equal
the rat small intestine and colon resulting from size. Each piece was quickly but gently spread
co-administration of L-NAME and a lipopoly- out on a glass microscope slide and then placed
saccharide. This could be inhibited by prior in a moist atmosphere at 37C. Specimens were
administration of a cyclooxygenase inhibitor, a then flooded either with NS or with NS plus a
thromboxane synthase inhibitor, a platelet acti- putative antagonist for 5 min. The bathing fluid
vating factor (PAF)-receptor antagonist
5 or a 5- was then drained away and replaced either by
lipoxygenase inhibitor. some fresh NS, NS plus antagonist, NS plus
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agonist, or NS plus antagonist plus agonist. Incu- 2.5 ml NS using a vortex mixer and heated for 10
bation continued for a further 15 min. Specimens min to 60C to release all remaining cellular his-
were then quickly drained, washed briefly with tamine. After cooling, two i ml aliquots of this
distilled water and covered with a solution of fluid were assayed for their histamine content as
0.05% toluidine blue in Mcllvaine’s buffer at pH4 above. Histamine released during incubation at
for 8 min. After a further quick wash in distilled 37C was expressed as a percentage of the total
water, each specimen was covered with a glass histamine originally present in the cells, and was
coverslip and viewed on the stage of a micro- corrected for the histamine released under
scope at x 100 magnification. This protocol was appropriate control conditions. One assay com-
found during pilot experiments to give good dif- prises the results obtained from one 0.5 ml
ferential staining of mast cells. The numbers of aliquot of mast cell-rich suspension. Mast cells
metachromatically (pink/magenta)-stained and from a minimum of three rats were used for
darkly blue-stained mast cells associated with each treatment group. The total numbers of
each milky spot were counted. The mean assays performed per treatment were between
number of such mast cells per milky spot in seven and 22. Putative agonists used were PMXB,
each piece of omentum was then calculated. The L-NAME, PAF or U46619. Putative antagonists
numbers of milky spots in each piece of used were SNP and BN52021.
omentum varied from 6 to 51, with most being
around 25-35. Statistics: Bonferroni’s test was used for compar-
Compounds tested as possible agonists were: ing several groups with one control group.
L-NAME, an NO-synthase inhibitor;
7 PAF, a
known inflammatory mediator;
8 U46619, a Chemicals used: L-NAME, PMXB, PAF, U46619,
thromboxane-mimetic;
9 and polymixin B BZI, NDGA, compound 48/80, and OPT were all
(PMXB) and compound 48/80, which are both obtained from Sigma Chemical Co. Ltd (Poole,
known to degranulate mast cells. Compounds UK); SNP was obtained from David Bull Labora-
used as possible antagonists were: indomethacin, tories (Warwick, UK); indomethacin from Merck,
a cyclooxygenase inhibitor;
11 SNP, an NO Sharpe & Dohme Ltd (Hoddesdon, UK); tolui-
12 donor; 1-benzylimidazole (BZI), a thrombox- dine blue (batch 9244890D) from BDH (Poole,
ane synthase inhibitor; BN52021, a specific PAF. UK). BN52021 was a gift from Dr P. Braquet,
receptor antagonist;
4 and nordihydroguaiaretc Institut Henri Beaufour (Le Plessis-Robinson,
acid (NDGA), a 5-1ipoxygenase inhibitor.5 France). L-NAME, PMXB, compound 48/80, BZI,
SNP and indomethacin were used as aqueous
Histamine release from peritoneal mast cells: solutions, indomethacin being dissolved with the
Female rats were killed as above. Then 40 ml of aid of a little NaiCO. NDGA and BN52021 were
NS at 37C was injected into each peritoneal dissolved initially in dimethylsulphoxide, the find
cavity and left for 15 min, massaging the concentration of solvent being <0.5%. U46619,
abdomen gently from time to time. Approx- as a concentrate in methyl acetate, and PAF, as a
imately 35 ml of mast cell rich-fluid was recover- concentrate in chloroform, were diluted with a
able from each animal. After spinning the fluid at little ethanol before final dilution with NS. OPT
670 x g, the resultant cell pelletwas re-suspended was dissolved in analytical grade methanol.
in NS and then spun again for a total of three
times. Finally the pellet was re-suspended in 5 ml Results NS, and 0.5 ml aliquots of mast cell-rich suspen-
sion were placed in each of 10 tubes. A further Treatment of the rat omentum in vitro with
0.4 ml of NS or of NS plus a putative antagonist either PMXB (1 mg/ml) or compound 48/80 (1
was then added to each tube. Cell suspensions tg/ml) (Fig. 1) or L-NAME (100 l,tM) (Fig. 2)or
were incubated at 37C for 10 min, agitating PAF (5 btM) or U46619 (1 l,tM) (Fig. 3) sig-
gently from time to time. Then 0.1 ml of NS or nificantly reduced the number of metachromatic-
of NS plus putative agonist was added to each ally stained OMCs in the milky spots. Lower con-
tube and incubation continued for a further 15 centrations of L-NAME (10 btM) or PAF (0.5 lm)
min, at which time histamine release was or U46619 (0.1 l,tM), however, were without a
stopped by adding 1.5 ml ice-cold NS and significant effect. OMCs that were either sub-
placing the tubes in melting ice. After spinning stantially or completely degranulated by such
the tubes at 670 x g for 10 min, two 1 ml ali- treatments stained darkly blue. The ratio of
quots from each supernatant were removed and .numbers of metachromatically stained OMCs to
assayed fluorimetrically for histamine using, 1% darkly blue-stained OMCs (M/DB) in the milky
phthaldialdehyde (OPT) as a fluorophore. spots was 6.3 ___
0.5 in the control preparations.
The residual cell pellet was re-suspended in Significant reductions in this ratio (p < 0.05,
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CONTROL
PMXB lmg/ml
48/80 ll.tg/ml
SNP 10t.tM
INDO llaM
BZI 5btM
BZI 501aM
BN 10btM
0 5 10 15 2’0 2’5
Mast Cell Counts
FIG. 1. Effects of various agents on the degranulation of rat
omental mast cells, aMast cell counts are the mean numbers -t-
SEM of metachromatically stained mast cells per omental milky
spot. *lower than, +higher than the control value (p < 0.05,
Bonferroni’s test). Abbreviations not used in the text: INDO, indo-
methacin; BN, BN52021.
CONTROL
L-NAME 1001.tM
L-NAME 101.tM
L-NAME 1001.tM + SNP 10btM
L-NAME 1001LtM INDO lbtM
L-NAME 100btM BZI 501.tM
L-NAME 1001.tM BZI 51a,M
L-NAME 1001a.M + BN 101.tM__- +
L-NAME 1001LtM NDGA 30btM
L-NAME 100btM + NDGA 31aM
0 5 10 1’5 2’0 2’5
Mast Cell Counts
FIG. 2. The degranulating effect of L-NAME on rat omental mast
cells, and its modification by various agents, aMast cell counts
are the mean numbers ___
SEM of metachromatically stained
mast cells per omental milky spot. *lower than control value (p
< 0.05, Bonferroni’s test); +higher than the value for L-NAME
100 pM (p < 0.05, Bonferroni’s test). Abbreviations not used in
the text: INDO, indomethacin; BN, BN52021.
Bonferroni’s test) occurred after treatment with
PMXB (to 0.06 ___
0.02), with 100 l.tM L-NAME
(to 3.4 0.4) and with 5 I.tM PAF (to 2.8
0.6). Reductions in the M/DB ratio after treat-
ment with compound 48/80 (to 4.0 ___
0.5) or
with 1 btM U46619 (to 4.6 0.6) did not quite
reach conventional levels of statistical sig-
nificance. Pre-treating the omentum with SNP (10
btM), with indomethacin (1 l.tM), with BZI (5 or
50 l.tM) or with BN52021 (10 I.tM) significantly
reduced the degranulating effects of L-NAME
(Fig. 2). Of these antagonists, however, only
indomethacin (Fig. 1) gave significant protection
against the disappearance of pink/magenta-
stained OMCs in NS-treated omenta during incu-
bation at 37C, and this was accompanied by a
significant increase in the M/DB ratio (to 10.5 ___
0.9). There was also a significant increase in the
M/DB ratio after pre-treatment with SNP (to 12.6 ___
1.0), but with this drug the increase in the
number of metachromatically stained OMCs per
milky spot did not reach a conventionai level of
statistical significance (Fig. 1). Pre-treatment of
the omentum with NDGA (3 or 30 l.tM) did not
reduce the effects of L-NAME significantly (Fig.
2). In contrast, pre-treatment with BN52021 (10
l.tM) significantly reduced the degranulating
effects of PAF (Fig. 3), whereas a lower con-
centration (1 l.tM) was not significantly effective.
Pre-treatment of the omentum with BZI (50 l.tM)
had no effect on the response to PAF. Pre-treat-
ment with BN52021 (10 l.tM), however, sig-
nificantly reduced the degranulating effects of
U46619 (Fig. 3).
PMCs responded to the addition of PMXB,
PAF or U46619 with a significant increase in his-
tamine release (Fig. 4). SNP, on the other hand,
significantly decreased the release of histamine
from PMCs (Fig. 4). In contrast to its mast cell-
degranulating effect in OMCs (see above), L-
NAME exerted no significant effect on the release
of histamine from PMCs (Fig. 4). However, pre-
treatment of PMCs with BN52021 (10 l.tM) sig-
nificantl attenuated the histamine-releasing effect
of PAF, but not that of U46619 (Fig. 4). In the
presence of L-NAME (100 l.tM) histamine release
in response to incubation with PAF or U46619
was increased but only slightly (Fig. 4).
Discussion
Endogenous NO has been shown to exert
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CONTROL
PAF 5btM
PAF 0.5btM
PAF 51.tM + BN 101.tM
PAF 51M + BZI 50btM
U46619 llaM
U46619 0.11.tM
U46619 lktM BN 10/aM
0 5 10
Mast Cell Counts
FIG. 3. The degranulating effects of PAF and U46619 on rat
omental mast cells, and their modification by BN52021 (BN) or
BZI. aMast cell counts are the mean numbers ___
SEM of meta-
chromatically stained mast cells per omental milky spot. *lower
than control value (p < 0.05, Bonferroni’s test); +higher than the
value for PAF 5 IM (p < 0.05, Bonferroni’s test); ++higher than
the value for U46619 IM (p < 0.05, Bonferroni’s test).
both anti-inflammatory and pro-inflammatory
effects, depending upon the circumstances.7’18
In acute gastrointestinal injury there is substantial
evidence to su&gest that NO has an anti-inflam-
matory effect, whereas a pro-inflammatory
effect is sometimes more evident during inflam-
mation occurring elsewhere in the body.
8 It has
been shown previously that administration of L-
NAME, which would be expected to have inhib-
ited NO-synthase, caused leakage of albumin
and of injected colloidal carboff’ from rat small
intestines and mesentery that apparently was due
to a release of certain mast cell-derived amines.
In the present experiments the application of L-
NAME caused degranulation of OMCs in the
milky spots. In contrast, pre-treatment with SNP,
an NO donor, counteracted this degranulation
(Fig. 2), suggesting that where OMCs are con-
cerned, both exogenous and endogenous NO
can be protective. However, in which of the
various omental cell type(s) the synthesis of NO
was actually being blocked by added L-NAME
remains unknown. In contrast, L-NAME did not
increase histamine release from PMCs (Fig. 4).
This observation is similar to that of other
workers who used A/-monomethyl-t-arginine as
19 an NO-synthase inhibitor. Perhaps resting PMCs
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CONTROL
PMXB lmg/ml
L-NAME 1001aM -’/
PAF 51.tM
PAF + BN 10btM
PAF + L-NAME 100t.tM
U46619 ll.tM
U46619 + BN 10btM
U46619 + L-NAME 100btM
SNP IOIM "ff
-Jo -io -io o 1’0 2’0 3’0 40
% Alteration in Histamine Release
FIG. 4. Effects of various agents on histamine release from rat
isolated peritoneal mast cells expressed as percentage increase
or decrease -t- SEM, after allowance for release in the appro-
priate controls. *p < 0.05, Bonferroni’s test, compared with the
control value. +p < 0.05, Bonferroni’s test, compared with the
value for PAF 5 IM.
have too low a cytoplasmic calcium ion con-
centration to permit activation of the constitutive
form of NO-synthase. If so, then L-NAME would
have no enzyme activity to inhibit. However,
under certain circumstances, such as during stir-
ring or incubation with lipopolysaccharide, PMCs
in vitro do respond to treatment with L-NAME or
other NO-synthase inhibitors with an enhanced
release of histamine.9 In the present experi-
ments, however, L-NAME only slightly augmented
the release of histamine that was produced in
PMCs by adding PAF or U46619 (Fig. 4). The
reasons for these discrepancies are presently
unknown.
Successful antagonism of the degranulating
effect of L-NAME on OMCs by pre-incubation
with indomethacin, BZI, or BN52021 (Fig. 2)
suggests that such degranulation may have been
in response to the release of endogenous throm-
boxane A2 (TXA2) and PAF; but from which of
the many cell types to be found within the
omentum this release occurs is unknown. It is
possible that different cell types may be respon-
sible for secretion of the two agents. Since the
degranulating effect of exogenously applied
U46619 in OMCs, although not PMCs, was fullyNO-synthase inhibition and mast cells
blocked by pre-treatment with BN52021, it is
likely that the exogenous thromboxane-mimetic
was first releasing PAF from the omentum and,
therefore, that most of the OMC degranulation
seen was due to this PAF, rather than to any
direct effect that U46619 also can exert upon
OMCs. The degranulating effect of exogenous
PAF was blocked by pre-treatment of the
omentum with BN52021, as would be expected,
but it was not blocked by pre-treatment with
BZI. This suggests, therefore, that in the presence
of L-NAME there may be a release of wxa2 within
the omentum, which in turn releases substantial
quantities of endogenous PAF. It may be the
degranulating effects of the latter substance,
therefore, that were being observed in incubated
omenta in the present experiments.
Pre-treatment of the isolated omentum with
NDGA in the present work did not affect the
extent of L-NAME-induced degranulation of
OMCs. This observation contrasts with a previous
report that BW A137C, another 5-1ipoxygenase
inhibitor, could ameliorate the combined effects
of L-NAME and lipopolysaccharide in provoking
the vascular leakage of albumin,
6 as also did
indomethacin, BZI and BN52021.
5 By being able
to secrete leukotrienes as well as prostaglandin D2,
mucosal mast cells would appear to be phenotyp-
ically rather different from the connective tissue
variety, since the latter can secrete only minute
amounts of leukotrienes.
2 Moreover, OMCs
appear to be of the connective tissue type, since
Fig. 1 shows that they were degranulated in
response to an application of compound 48/80,
as were mesenteric and peritoneal mast cells in
other earlier experiments,
21 whereas mucosal
mast cells were not.
21 However, we are aware
that NDGA, unlike BW A137C, has non-specific
antioxidant properties. This might account for its
lack of effect in the present experiments.
The protective effect of indomethacin on
omental mast cells (Fig. 2) is interesting, since
inhibiting cyclooxygenase with this drug would
be expected to reduce the availability of both
prostaglandins and wxa2. Prostaglandins,
however, appear to lack a regulatory effect on
22 mast cells. Consequently, only the effect of
inhibiting wxa2 production with indomethacin is
likely to be evident in the isolated omentum. The
overall effect of the drug, therefore, would be a
reduced degranulation, an effect similar to that of
BZI (Fig. 2), which was used to inhibit the synth-
esis of wxa2 selectively. It appears that metabolic
processes in the mast cell are finely balanced,
but they can be pushed by various pharmacolo-
gical means either towards cellular protection, for
example, by inhibiting wxa2 synthesis, or
towards cellular damage, by inhibiting NO synth-
esis. It seems likely that mucosal and omental
mast cells react in pharmacologically similar
ways. We hope to investigate this hypothesis
further, but meanwhile we may conclude that the
effects of L-NAME on mast cell degranulation in
the rat intestine, mesentery and omentum are
rather similar processes, involving a destabilizing
influence of endogenous wxa2 and PAF, possibly
acting sequentially.
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